GS2-05: "Randomized comparison of adjuvant aromatase inhibitor exemestane (E) pl
GS3-08 Discussant
GS3-04: Discussant
GS3-07: "Circulating tumor DNA (ctDNA) dynamics in patients with hormone recepto
GS3-01: "Trastuzumab deruxtecan vs trastuzumab emtansine in patients with HER2+
GS3-10：“samuraciclib（CT7001）的研究，这是一种首创的CDK7口服选择性抑制剂。
GS3-03: "Genomic analysis of 733 HER2+ breast cancers identifies recurrent pathw
GS3-09: "Loss of ASXL1 tumor suppressor promotes resistance to CDK4/6 inhibitors
GS2-04: "Aromatase inhibitors versus tamoxifen in pre-menopausal women with estr
TEAD inhibitor IK-930: a promising targeted therapy for mesothelioma
GS3-02. Updated overall survival (OS) results from the phase 3 PHOEBE trial
Educational Sessions: "IO vs Capecitabine for TNBC"
GS3-06: "Primary results of the cTRAK TN trial: A clinical trial utilising ctDNA
MESOMICS: molecular characterization of malignant pleural mesothelioma
Immune checkpoint inhibitors in mCRPC
Spotlight Poster Discussion: "Novel immunotherapy approaches"
Educational Sessions: "Optimizing immunotherapy efficacy in the clinic through b
辩论：RxPONDER：“这都是OFS吗？亲
THOR: erdafitinib in metastatic urothelial cancer with FGFR alterations
Optimal therapy sequencing in kidney cancer
